Hacker News new | past | comments | ask | show | jobs | submit
It sucks less than existing chemo:

> Treatment-related adverse events that led to treatment discontinuation occurred in 1.2% of the patients in the daraxonrasib group and in 11.2% of those in the chemotherapy group.

That's a huge reduction in side effects bad enough to stop treatment.

https://www.nejm.org/doi/full/10.1056/NEJMoa2605555?